Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef Leibold

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Signal Transduction and Targeted Therapy|January 21, 2025
Immunotherapy in ovarian cancer: spatial functional genomics to unravel resistance mechanismsMartina Rausch, Karlotta Bartels, Josef Leibold
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Induction of Thelper1-driven antiviral T-cell lines for adoptive immunotherapy is determined by differential expression of IFN-γ and T-cell activation markersJosef Leibold, Judith Feucht, Ameli Halder, et al.
Deutsche Medizinische Wochenschrift (1946)|June 30, 2012
[42-year-old patient with portal hypertension - case 6/2012]Josef Leibold, Serkan Karakaya, Birgit Federmann, et al.
Nature Medicine|December 19, 2018
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potencyJudith Feucht, Jie Sun, Justin Eyquem, et al.
Nature Medicine|January 30, 2019
Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potencyJudith Feucht, Jie Sun, Justin Eyquem, et al.
Theranostics|February 16, 2026
Modeling immunotherapies in live 3D human cancer tissue bioreactorsYizheng Zhang, Ivan Foth, Ahmad Makky, et al.
Nature Cancer|January 4, 2024
Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic diseaseJosef Leibold, Kaloyan M Tsanov, Corina Amor, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 27, 2022
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancerStella V Paffenholz, Camilla Salvagno, Yu-Jui Ho, et al.
Cancer Discovery|February 26, 2026
Integrated chronic in vivo and in vitro screens uncover NFIL3 as a driver of T cell dysfunctionNayan Jain, Yuzhe Shi, Celina May, et al.
Cell|August 10, 2019
The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-KinaseViraj R Sanghvi, Josef Leibold, Marco Mina, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Signal Transduction and Targeted Therapy|January 21, 2025
Immunotherapy in ovarian cancer: spatial functional genomics to unravel resistance mechanismsMartina Rausch, Karlotta Bartels, Josef Leibold
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Induction of Thelper1-driven antiviral T-cell lines for adoptive immunotherapy is determined by differential expression of IFN-γ and T-cell activation markersJosef Leibold, Judith Feucht, Ameli Halder, et al.
Deutsche Medizinische Wochenschrift (1946)|June 30, 2012
[42-year-old patient with portal hypertension - case 6/2012]Josef Leibold, Serkan Karakaya, Birgit Federmann, et al.
Nature Medicine|December 19, 2018
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potencyJudith Feucht, Jie Sun, Justin Eyquem, et al.
Nature Medicine|January 30, 2019
Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potencyJudith Feucht, Jie Sun, Justin Eyquem, et al.
Theranostics|February 16, 2026
Modeling immunotherapies in live 3D human cancer tissue bioreactorsYizheng Zhang, Ivan Foth, Ahmad Makky, et al.
Nature Cancer|January 4, 2024
Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic diseaseJosef Leibold, Kaloyan M Tsanov, Corina Amor, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 27, 2022
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancerStella V Paffenholz, Camilla Salvagno, Yu-Jui Ho, et al.
Cancer Discovery|February 26, 2026
Integrated chronic in vivo and in vitro screens uncover NFIL3 as a driver of T cell dysfunctionNayan Jain, Yuzhe Shi, Celina May, et al.
Cell|August 10, 2019
The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-KinaseViraj R Sanghvi, Josef Leibold, Marco Mina, et al.
Pageof 3